<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158610</url>
  </required_header>
  <id_info>
    <org_study_id>BIG-MOON</org_study_id>
    <nct_id>NCT03158610</nct_id>
  </id_info>
  <brief_title>Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer</brief_title>
  <official_title>Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based upon biological behavior, those mCRC patients who respond well (SD, PR or CR according
      to RECIST Criteria) after 16-18 weeks of standard doublet chemotherapy as induction may
      enrolled into this study, randomly divided into capecitabine metronomic group or standard
      dosage group. The duration of disease control after randomization(PFS2) and progression free
      survival from enrollment (PFS1) are primary endpoints. Meanwhile, the overall survival,
      safety and quality of life are secondary endpoints. Exploratory markers involving
      angiogenesis (serum VEGF, PDGF, Tie-1 and Tie2, etc) and immune function (CD clusters, serum
      tumor mutation burden(TMB), etc), are conducted via liquid biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is try to evaluate the effect of capecitabine metronomic chemotherapy as
      maintenance treatment, which compare to capecitabine conventional chemotherapy, who have
      responded to 16-18 months first-line chemotherapy in metastatic colorectal cancer (mCRC). The
      maintenance treatments are continued until disease progression or severe toxicity. The aim of
      this study is to demonstrate that capecitabine metronomic chemotherapy is non-inferior to
      capecitabine conventional chemotherapy. Furthermore, exploratory markers involving
      angiogenesis (serum VEGF, PDGF, Tie-1 and Tie2, etc) and immune function (CD clusters, serum
      tumor mutation burden(TMB), etc), are conducted via liquid biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival 1 (PFS1)</measure>
    <time_frame>10 months</time_frame>
    <description>from enrollment to progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival 2 (PFS2)</measure>
    <time_frame>4 months</time_frame>
    <description>from randomization to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>20 months</time_frame>
    <description>from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>20 months</time_frame>
    <description>drug related toxicity from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with quality of life (QoL) as assessed by CTCAE v4.0</measure>
    <time_frame>20 months</time_frame>
    <description>QoL from signing informed consent to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine metronomic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine 500mg/m2 bid po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine standard dosage chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1000mg/m2 bid po d1-d14,q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral fluorouracil</description>
    <arm_group_label>Capecitabine metronomic chemotherapy</arm_group_label>
    <arm_group_label>Capecitabine standard dosage chemotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Before the start of induction therapy:

        Inclusion Criteria:

          -  Histological proof of colorectal cancer (in case of a single metastasis, histological
             or cytological proof of this lesion should be obtained);

          -  Distant metastases which are unresectable (patients with only local recurrence are not
             eligible);

          -  Measurable disease (&gt; 1 cm on spiral CT scan or &gt; 2 cm on chest X-ray; liver
             ultrasound is not allowed). Serum CEA may not be used as a parameter for disease
             evaluation;

        Exclusion criteria

          -  Prior adjuvant treatment for stage II/III colorectal cancer ending within 6 months
             before the start of induction treatment

          -  Any prior adjuvant treatment after resection of distant metastases

          -  Previous systemic treatment for advanced disease

        At randomisation:

        Inclusion criteria:

          -  WHO performance status 0-1 (Karnofsky PS &gt; 70%);

          -  Disease evaluation with proven SD, PR or CR according to RECIST after first-line
             induction treatment;

          -  Laboratory values obtained ≤ 2 weeks prior to randomisation: adequate bone marrow
             function (Hb &gt; 6.0 mmol/L, absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x
             109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft
             formula, &gt; 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases
             ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver
             metastases);

          -  Life expectancy &gt; 12 weeks;

          -  Age: 18-75 years;

          -  Negative pregnancy test in women with childbearing potential;

          -  Expected adequacy of follow-up;

          -  Institutional Review Board approval;

          -  Written informed consent Exclusion criteria

          -  Chronic active infection;

          -  Any other concurrent severe or uncontrolled disease preventing the safe administration
             of study drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015 Mar 28;358(2):100-106. doi: 10.1016/j.canlet.2014.12.039. Epub 2014 Dec 23. Review.</citation>
    <PMID>25541061</PMID>
  </reference>
  <reference>
    <citation>Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.</citation>
    <PMID>16421419</PMID>
  </reference>
  <reference>
    <citation>André T, Tournigand C, Mineur L, Fellague-Chebra R, Flesch M, Mabro M, Hebbar M, Postel Vinay S, Bidard FC, Louvet C, de Gramont A; GERCOR (French Oncology Research Group). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol. 2007 Jan;18(1):77-81. Epub 2006 Oct 9.</citation>
    <PMID>17030548</PMID>
  </reference>
  <reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Deputy-chief of Department of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

